雷贝拉唑联合氟哌噻吨美利曲辛片治疗慢性萎缩性胃炎患者的疗效及对血清sIL-2R MDA G-17的影响  

Curative Effect of Rabeprazole Combined with Droperitiazole Meretroxine in the Treatment of Patients with Chronic Atrophic Gastritis and its Effect on Serum sIL-2R MDA and G-17

作　　者：王剑 陈志涛[1] 周婷婷 廖宇圣[1] WANG Jian;CHEN Zhitao;ZHOU Tingting(Wuhan Central Hospital, Hubei Wuhan 430000, China)

机构地区：[1]湖北省武汉市中心医院消化内科

出　　处：《河北医学》2019年第8期1333-1336,共4页Hebei Medicine

基　　金：湖北省自然科学基金项目,(编号:2013082);湖北省武汉市卫生局项目,(编号:WX13A07)

摘　　要：目的:观察雷贝拉唑联合氟哌噻吨美利曲辛片治疗慢性萎缩性胃炎患者的疗效及对血清可溶性白细胞介素-2受体(sIL-2R)、丙二醛(MDA)、胃泌素-17(G-17)的影响.方法:96例慢性萎缩性胃炎患者来自于我院2015年12月至2017年12月,按简单随机数字表法分为对照组和研究组,每组48例,对照组采用雷贝拉唑治疗,研究组采用氟哌噻吨美利曲辛片联合雷贝拉唑治疗.比较两组疗效,SF-36量表评分,焦虑抑郁评分及症状评分,sIL-2R,MDA,G-17,及不良反应发生情况.结果:研究组总有效率95.83%显著高于对照组79.18%(P<0.05).治疗前,比较两组SF-36量表评分,焦虑抑郁评分及症状评分,sIL-2R,MDA,G-17比较无统计学差异(P>0.05);治疗后2周、治疗后4周,两组SF-36量表评分,G-17均显著上升,研究组明显高于对照组,两组焦虑抑郁评分及症状评分,sIL-2R,MDA均显著降低,研究组显著低于对照组,差异有统计学意义(P<0.05).两组不良反应发生率比较差异无统计学意义(P>0.05).结论:雷贝拉唑联合氟哌噻吨美利曲辛片治疗慢性萎缩性胃炎的疗效肯定,能够明显改善患者临床症状,提高健康状态,可能与其更有利于sIL-2R、MDA、G-17水平调控有关.Objective: To observe the curative effect of rabeprazole combined with droperitiazole meretroxine in the treatment of patients with chronic atrophic gastritis and its effect on serum soluble interleukin-2 receptor (sIL -2R), malondialdehyde (MDA) and gastric secrete element-17 (G-17). Methods: 96 cases of chronic atrophic gastritis patients from December 2015 to December 2017, according to the simple random number table method these patients were divided into control group and research group,48 cases in each group. control group was treated with rabeprazole, and the research group was treated with flupipertiazol tablet united rabeprazole. Then curative effect, SF-36 scale score, anxiety, depression scores and symptom scores,sIL-2R,MDA,G-17, and adverse reactions occur between two group were and compared. Results:: Total effective rate of the experimental group 95.83% was significantly higher than the control group 79.18%(P<0.05). Before treatment, SF-36 scale score, anxiety, depression scores and symptom scores,sIL-2R,MDA,G-17 of two group was no statistically significant (P>0.05). 2 weeks after treatment, 4 weeks after treatment, SF-36 scale score, G-17 of experimental group was significantly increased than after the treatment, the treatment group was significantly higher than the control group, anxiety depression scale and symptom scores, sIL-2R, MDA of two group was significantly reduced than after treatment, the experimental group was significantly lower than the control group,the difference was statistically significant (P<0.05). The adverse effects rate in both group was no statistical significance (P>0.05). Conclusion:: curative effect of rabeprazole combined with droperitiazole meretroxine in the treatment of patients with chronic atrophic gastritis is sure, can significantly improve the clinical symptoms of patients,improve health,,it may be more conducive to regulating sIL-2R, MDA, and G-17 levels.

关 键 词：慢性萎缩性胃炎 雷贝拉唑 氟哌噻吨美利曲辛片 可溶性白细胞介素-2受体 丙二醛 胃泌素-17 

分 类 号：R573.32[医药卫生—消化系统]